Health economics of asthma and rhinitis. II. Assessing the value of interventions

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 2, 2001, Pages 203-210

  Sullivan, Sean D ^a   Weiss, Kevin B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Allergic rhinitis; Asthma; Cost effectiveness analysis; Costs; Economics

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; FORMOTEROL; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; NEDOCROMIL; SALBUTAMOL; TERBUTALINE; TERFENADINE; ZAFIRLUKAST;

ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; EMERGENCY WARD; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HUMAN; LUNG FUNCTION TEST; MEDICAL DECISION MAKING; PATIENT EDUCATION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; SPIROMETRY;

EID: 0035116774     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.112851     Document Type: Article

References (100)

1. Ethical issues in managed care
2. The health economics of asthma and rhinitis. I. Assessing the economic impact
3. Theoretical foundations of cost-effectiveness analysis
4. National asthma education and prevention program working group report on the cost-effectiveness of asthma care
5. Active detection of chronic obstructive pulmonary disease and asthma in the general population
6. Effectiveness of leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: A randomized, double-blind, placebo-controlled trial
7. Is high-dose fluticasone propionate via a metered-dose inhaler and volumatic as efficacious as nebulized budesonide in adult asthmatics?
8. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma
9. A comparison of the cost effectiveness of altenative prophylactic therapies in childhood asthma
10. A comparison of the cost-effectiveness of budesonide 400 μg/day and 800 μg/day in the management of mild-to-moderate asthma in general practice
11. Episode-free days as endpoints in economic evaluations of asthma therapy
12. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100 microgram versus fluticasone propionate 100 microgram in adults and adolescents with asthma. III: Results
13. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 microgram versus fluticasone propionate 250 micrograms versus fluticasone propionate 250 micrograms in adults and adolescents with asthma. IV: Results
14. Cost-effectiveness analysis of salmeterol/fluticasone 50/500 micrograms versus fluticasone propionate 500 micrograms in patients with corticosteroid-dependent asthma. V: Results
15. Efficacy and safety of inhaled corticosteroids in asthma
16. Long-term effects of budesonide or nedocromil in children with asthma
17. Impact of inhaled corticosteroids on acute asthma hospitalization in Sweden 1978-1991
18. Fluticasone propionate: An audit of outcomes and cost-effectiveness in primary care
19. Outcomes and cost-benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients
20. Advantages of high-dose inhaled budesonide
21. Efficacy and cost effectiveness of inhaled steroids in asthma in a developing country
22. Asthma treatment costs using inhaled corticosteroids
23. Which clinical studies provide the best evidence? The best RCT still trumps the best observational study
24. Randomized trials of observational tribulations?
25. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care
26. The cost-effectiveness of budesonide in severe asthmatics aged one to three years
27. Cost-effectiveness of inhaled corticosteroid plus bronchodilator therapy versus bronchodilator monotherapy in children with asthma
28. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease
29. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children
30. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma
31. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micrograms twice daily and budesonide 800 micrograms twice daily in the treatment of adults and adolescents with asthma
32. Cost-effectiveness of including cromolyn sodium in the treatment program for asthma: A retrospective, record-based study
33. A retrospective assessment of cost avoidance associated with the use of nedocromil sodium metered-dose inhaler in the treatment of patients with asthma
34. Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma
35. Cost-effectiveness of inhaled beta-agonists versus oral salbutamol in asthma: A randomized double blind cross over study
36. Assessing costs of aerosol therapy
37. Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients
38. Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care
39. Substitution of metered-dose inhalers for hand-held nebulizers: Success and cost savings in a large, acute-care hospital
40. Cost impact of metered dose inhalers vs small volume nebulizers in hospitalized patients: The Cleveland Clinic experience
41. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients
42. Holding chambers versus nebulizers for beta agonist treatment of acute asthma (Cochrane Review)
43. A cost-effectiveness analysis of breath-actuated metered-dose inhalers
44. The technology of metered-dose inhalers and treatment costs in asthma: A retrospective study of breath actuation versus traditional press-and-breathe inhalers
45. Cost-effectiveness analysis of a dry powder inhaler (Turbuhaler) versus a pressurized metered dose inhaler in patients with asthma
46. Toward cost-benefit evaluations of health education: Some concepts, methods and examples
47. Asthma education
48. Evaluation of the efficacy and cost effectiveness of health education methods to increase medication adherence among adults with asthma
49. Evaluation of a structured treatment and teaching programme on asthma
50. Asthma self-management programs can reduce the need for hospital-based asthma care
51. Cost-effectiveness of a structured treatment and teaching programme on asthma
52. The cost and effectiveness of an education program for adults who have asthma
53. The economics of an intensive education programme for asthmatic patients: A prospective controlled trial
54. Teaching self-management skills to asthmatic children and their parents in an ambulatory care setting
55. A randomized trial of ACT (asthma care training) for kids
56. The impact of health education on frequency and cost of health care use by low income children with asthma
57. Economic analysis of two structured treatment and teaching programs on asthma
58. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland
59. One-year economic evaluation of intensive vs conventional patient education and supervision for self-management of new asthmatic patients
60. Reductions in hospital use from self management training for chronic asthmatics
61. The Kansas City asthma care project: Specialty differences in the costs of treating asthma
62. Cost effectiveness of an allergy consultation in the management of asthma
63. Use of the emergency department observation unit in the treatment of acute asthma
64. Impact of a short stay unit on asthma patients admitted to a tertiary pediatric hospital
65. Emergency department observation unit versus hospital inpatient care for a chronic asthmatic population
66. An intervention program to reduce the hospitalization cost of asthma patients requiring intubation
67. A cost-saving algorithm for children hospitalized for status asthmaticus
68. Impact of clinical pathways and practice guidelines on the management of acute exacerbations of bronchial asthma
69. One-year experience with an inpatient asthma clinical pathway
70. Disease management
71. Disease management: New wine in new bottles?
72. From outcomes research to disease management: A guide for the perplexed
73. Integrated care for asthma: A clinical, social, and economic evaluation. Grampian Asthma Study of Integrated Care
74. Outcomes evaluation of a comprehensive intervention program for asthmatic children enrolled in Medicaid
75. Pediatric asthma outcomes after implementation of a disease management model: The Asthmatter of Fact Program
76. Cost-effective management of malignant potentially fatal asthma
77. Disease management program improves asthma outcomes
78. A randomized controlled trial of a pediatric asthma outreach program
79. Decrease in emergency room or urgent care visits due to management of bronchial asthma inpatients and outpatients with pharmaceutical services
80. Computer-generated intervention for asthma population care management
81. The impact of disease management on outcomes and costs of care: A study of low-income asthma patients
82. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma
83. Cost-benefit analysis of psychosomatic therapy in asthma
84. Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting
85. Measurement of outcomes in adults receiving pharmaceutical care in a comprehensive asthma outpatient clinic
86. The facilitator effect: Results from a four-year follow-up of children with asthma
87. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis
88. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis
89. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis
90. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany
91. Economic outcomes of a targeted intervention program: The costs of treating allergic rhinitis patients